Morningstar’s recent analysis suggests a "Buy" on Intellia Therapeutics, assigning a fair value of $85 per share, while the current trading price is significantly lower at $15.85.
Morningstar has issued a BUY recommendation on Sanofi SA, with an upgraded fair value target of $63 from $61 due to consistent revenue growth and strong performance in immunology and vaccine divisi